| Ytd | -3.44% | |
| 1y | 14.09% |
| Open | 4.02 | Prev Close | 3.92 | Low | 4.02 | High | 4.72 | Mkt Cap | 161.27M |
| Vol | 2.86K | Avg Vol | 3.59K | EPS | -1.65 | P/E | N/A | Forward P/E | -2.96 |
| Beta | 0.54 | Short Ratio | 4.49 | Inst. Own | 5.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-25 | 50-d Avg | 4.15 | 200-d Avg | 4.24 | 1yr Est | 10.37 |
MOLN News
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the ana
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting
Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving preci
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partne
Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosi
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712Dosing ongoing
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIR
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. , May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partner
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.45) per share which missed the ana
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announceme
ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partner
MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast a
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a B
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MS
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MS
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announce
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partn
Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partn
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partn
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schliere
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partne
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiot
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for it